Proteomic Testing May Enable NIV Diagnosis of Respiratory Pathologies in Preterm Newborns
By LabMedica International staff writers Posted on 19 Sep 2016 |
Image: Prof. Evgeny Nikovaev and senior fellow Alexey Kononikhin in front of the ultra high resolution MS instrument (Photo courtesy of the MIPT).
A team of researchers is developing its new method for noninvasive diagnosis and therapeutic response monitoring of conditions in preterm newborns based on marker sets now identified by proteome analysis of urine samples.
The majority of patients in neonatal intensive care units are premature babies, who often have respiratory conditions. It is important to distinguish whether their illness is due to infection or a failure in the developmental process. The composition of biological fluids (e.g. blood, urine, saliva) is highly complex, and most current diagnostic procedures for neonatal intensive therapy include sample collections that are invasive (e.g. biopsy) or semi-invasive (e.g. blood sampling).
Using high-performance mass spectrometry (HPMS; more specifically LC-MS/MS), experts from the Moscow Institute of Physics and Technology (MIPT; Moscow, Russia) are identifying different proteins and determining their concentrations in target fluids. Studies of the urinary proteome in pediatrics, especially in neonatology, are limited. In the new study, the team investigated the urine proteome of preterm newborns with respiratory pathologies. In order to further specify the defined infant-specific dataset, proteins were compared with the urinary proteome of healthy adults (men and pregnant women).
As a result bioinformatic processing of the HPMS data, the team singled out 36 proteins that indicate if respiratory pathologies are infectious (congenital pneumonia) or non-infectious (tachypnea, infant respiratory distress syndrome).
“In our pilot study, we succeeded in defining the core urinary proteome and proteins specific for infants and pathological conditions. We are pioneers in the non-invasive identification of urinary biomarkers diagnosing respiratory conditions in newborns. The results are optimistic and will serve as a platform to move forward in developing a method of monitoring conditions in newborns,” said team leader Prof. Evgeny Nikolaev, head of MIPT’s Laboratory of Ionic and Molecular Physics.
The study, by Starodubtseva NL, Kononikhin AS, et al, was published June 14, 2016, online ahead of print in the Journal of Proteomics.
Related Links:
Moscow Institute of Physics and Technology
The majority of patients in neonatal intensive care units are premature babies, who often have respiratory conditions. It is important to distinguish whether their illness is due to infection or a failure in the developmental process. The composition of biological fluids (e.g. blood, urine, saliva) is highly complex, and most current diagnostic procedures for neonatal intensive therapy include sample collections that are invasive (e.g. biopsy) or semi-invasive (e.g. blood sampling).
Using high-performance mass spectrometry (HPMS; more specifically LC-MS/MS), experts from the Moscow Institute of Physics and Technology (MIPT; Moscow, Russia) are identifying different proteins and determining their concentrations in target fluids. Studies of the urinary proteome in pediatrics, especially in neonatology, are limited. In the new study, the team investigated the urine proteome of preterm newborns with respiratory pathologies. In order to further specify the defined infant-specific dataset, proteins were compared with the urinary proteome of healthy adults (men and pregnant women).
As a result bioinformatic processing of the HPMS data, the team singled out 36 proteins that indicate if respiratory pathologies are infectious (congenital pneumonia) or non-infectious (tachypnea, infant respiratory distress syndrome).
“In our pilot study, we succeeded in defining the core urinary proteome and proteins specific for infants and pathological conditions. We are pioneers in the non-invasive identification of urinary biomarkers diagnosing respiratory conditions in newborns. The results are optimistic and will serve as a platform to move forward in developing a method of monitoring conditions in newborns,” said team leader Prof. Evgeny Nikolaev, head of MIPT’s Laboratory of Ionic and Molecular Physics.
The study, by Starodubtseva NL, Kononikhin AS, et al, was published June 14, 2016, online ahead of print in the Journal of Proteomics.
Related Links:
Moscow Institute of Physics and Technology
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines